Tanvex BioPharma, Inc.

Tanvex has received disappointing news on its US filing for a Herceptin (trastuzumab) biosimilar, with the US Food and Drug Administration issuing the firm with a complete response letter over its TX0

Lupin has announced the appointment of Claus Jepsen to become president of the Indian firm’s global specialty business, joining the firm from Takeda Pharmaceuticals, where he led the global strategy f

In an unscripted moment of synchronicity, the complete response letter for linvoseltamab announced by Regeneron Pharmaceuticals, Inc. on 20 August exemplified the findings of a US Food and Drug Admi